7 Recruiting Advanced Lung Non-Small Cell Carcinoma Phase 2 Clinical Trials
Active phase 2 studies for advanced lung non-small cell carcinoma enrolling across the USA. Verify eligibility and contact site coordinators.
All Advanced Lung Non-Small Cell Carcinoma studiesPhase 2 Studies for Advanced Lung Non-Small Cell Carcinoma
🔵 Active, Not Recruiting Phase1 / Phase2
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 / Phase3
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
📍 Veterans Administration Medical Center - Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase2
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer
📍 Roswell Park Cancer Institute — Buffalo, New York
View Study & Checklist ➔ 🟢 Recruiting Phase2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
View Study & Checklist ➔ 🟢 Recruiting Phase2
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
📍 Emory University Hospital Midtown — Atlanta, Georgia
View Study & Checklist ➔ 🟢 Recruiting Phase2
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
📍 Roswell Park Cancer Institute — Buffalo, New York
View Study & Checklist ➔ 🟢 Recruiting Phase2
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔